PDCD1 and ovarian carcinoma: MDA-MB-231 adenocarcinoma cells, a triple-negative breast cancer (TNBC) cell line, and SKOV3, and ovarian cancer cell line, were selected as both TNBC and ovarian cancer are targets of interest for checkpoint inhibitor therapy but have shown inadequate clinical success with PD1/PDL1 inhibition alone22,23.